Evaluation of the activity of RA and sustained remission in patients ongoing biological therapy
PDF BG/EN

Keywords

rheumatoid arthritis
biological therapy
remission
low disease activity

How to Cite

[1]
Shivacheva, T. 2019. Evaluation of the activity of RA and sustained remission in patients ongoing biological therapy. Revmatologiia (Bulgaria). 27, 1 (Apr. 2019), 16-23. DOI:https://doi.org/10.35465/27.1.2019.pp16-23.

Abstract

The aim of the study is to establish the frequency and sustained remission and low disease activity in patients with RA in the course of long-term treatment with synthetic and biological means (DMARDs) in real conditions. In the conditions of retrospective data analysis of real clinical practice, there were included 209 patients suffering from RA. Activity indexes of RA in all patients were analyzed in the last year of treatment with bDMARDs. The average age of the patients is 59,01 years old. The dominants sex is female (84.6%). The beginning of treatment with biological therapy is delayed with the average of 8.21 year. In all activity indexes of RA, which were monitored in the beginning of the 6th and the 12th months, there was established a significant difference in their variation for the periods surveyed. There is a general trend towards lowering the values of our indicators. In the beginning of the monitored period, the patients going into remission (DAS28 CRP) are approximately 3 times less – 11% (n = 23) in comparison with those in the end of the study – 32.99% (n = 64) (p < 0.001). In 10% of the cases a sustained remission is observed by both combined indexes (DAS28 ESR and DAS28 CRP) (p < 0.001). Today the accurate way is the “treat to target” strategy. The purpose is lowering the activity of the disease to very low levels (or remission) and achieving a long-term remission which is now real and achievable.

https://doi.org/10.35465/27.1.2019.pp16-23
PDF BG/EN

References

  1. Ajeganova S, Huizinga T. Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations. Ther Adv Musculoskelet Dis. 2017;9(10):249-262.
  2. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
  3. Bello, AE, Perkins, EL, Jay, R, Efthimiou, P. Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open access rheumatology: research and reviews, 2017, 9, 67-79.
  4. Bykerk VP. Rheumatoid arthritis: 2011 remission criteria are a new benchmark for RA therapy. Nat Rev Rheumatol. 2011, 7: 317-318.
  5. Cardiel М. Treat to Target Strategy in Rheumatoid Arthritis: Real Benefits Estrategia «treat to target» en la artritis reumatoide: beneficios reales. Reumatol Clin 2013;9:101-5.
  6. Felson DT, Smolen J, Wells G et al. Predictive validity of the new preliminary ACR/EULAR definitions for remission in rheumatoid arthritis. Arthritis Rheum. 2010, 62 (Suppl 10): 2108.
  7. Felson DT, Smolen JS, Wells G, Zhang B et al. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Arthritis Rheum. 2011, 63: 573- 586.
  8. Hochberg, M. C., Chang, R. W., Dwosh, I et al. The American college of rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis & Rheumatism, 1992,35: 498-502.
  9. Prevoo ML, Van t Hof MA, Kuper HH et al. Modifi ed disease ac- tivity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 44-48.
  10. Prince Femke HM, Vivian P Bykerk et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice, Arthritis Research & Therapy, 2012, 14:R68 https://doi. org/10.1186/ar3785
  11. Schoels М., Alasti F, et al. Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition, Arthritis Res Ther. 2017; 19: 155.
  12. Smolen JS, Breedveld FC, Schiff MH et al. A simplifi ed disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003, 42: 244-257.
  13. Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010, 69: 964-975.
  14. Smolen. JS. Treat-to-target: rationale and strategies. Clin Exp Rheumatol 2012; 30 (Suppl. 73):S2-S6
  15. Sokka T. Long-term outcomes of rheumatoid arthritis. Current Opin Rheumatol. 2009, 21: 284-290.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.